← Back to headlines
Eli Lilly Stock Swings Following FDA Liver Failure Report
Eli Lilly's stock experienced fluctuations after the FDA released a report concerning liver failure associated with one of its GLP-1 drugs.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
